| 2026-05-08 |
详情>>
股本变动：
变动后总股本20625.00万股
|
| 2026-05-08 |
详情>>
业绩披露：
2026年一季报每股收益0.33美元,归母净利润6804.30万美元,同比去年增长-25.03%
|
| 2026-05-06 |
财报披露：
美东时间 2026-05-06 盘后发布财报
|
| 2026-03-20 |
详情>>
业绩披露：
2023年年报每股收益1.50美元,归母净利润3.41亿美元,同比去年增长-19.35%
|
| 2026-03-20 |
详情>>
业绩披露：
2025年年报每股收益1.96美元,归母净利润4.25亿美元,同比去年增长408.28%
|
| 2026-01-21 |
复牌提示：
2026-01-20 11:26:50 停牌，复牌日期 2026-01-20 11:32:40
|
| 2025-12-18 |
详情>>
拆分方案：
每20.0000合并分成19.0000股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.46美元,归母净利润3.17亿美元,同比去年增长6801.56%
|
| 2025-08-21 |
详情>>
业绩披露：
2025年中报每股收益0.86美元,归母净利润1.87亿美元,同比去年增长281.94%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益0.42美元,归母净利润9075.80万美元,同比去年增长12.50%
|
| 2025-03-31 |
详情>>
业绩披露：
2022年年报每股收益1.86美元,归母净利润4.23亿美元,同比去年增长-17.44%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益0.38美元,归母净利润8359.10万美元,同比去年增长-75.51%
|
| 2025-01-21 |
详情>>
拆分方案：
每36.0000合并分成35.0000股
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.02美元,归母净利润-473.1万美元,同比去年增长-101.94%
|
| 2024-08-02 |
详情>>
业绩披露：
2024年中报每股收益-0.46美元,归母净利润-1.03亿美元,同比去年增长-161.99%
|
| 2024-05-01 |
详情>>
业绩披露：
2024年一季报每股收益0.36美元,归母净利润8067.30万美元,同比去年增长-5.13%
|
| 2024-01-30 |
详情>>
拆分方案：
每25.0000合并分成24.2500股
|
| 2023-11-01 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Opening
2.Managing Board Report for the year ended December 31, 2022 ("Calendar Year 2022")
3.Supervisory Board Report on the Company's Annual Accounts (the "Annual Accounts") for Calendar Year 2022
4.Adoption of the Annual Accounts for Calendar Year 2022
5.Advisory Vote on the Remuneration Report 2022
6.Reservation and dividend policy
7.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2022
8.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2022
9.Reappointment of the following eight Supervisory Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2024
10.Reappointment of the following two Managing Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2024
11.Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2023
12.Authorization of the Supervisory Board, until December 22, 2024 to (voting items):
(a)issue a number of ordinary shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of the shares issued and outstanding in the capital of the Company as at December 31, 2022 as included in the Annual Accounts for Calendar Year 2022;
(b)restrict or exclude the pre-emptive rights with respect to issuing ordinary shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2022
13.Authorization of the Managing Board, until December 22, 2024, to acquire shares in the Company's own share capital
14.Discretionary rights for the Managing Board to implement a capital repayment by means of a synthetic share repurchase (voting item):
(a)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment to the Company's Articles of Association (Part I) to, amongst other things, increase the par value per ordinary share in the share capital of the Company by an amount to be determined by the Managing Board of the Company;
(b)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment of the Company's Articles of Association (Part II) to, amongst other things, consolidate the ordinary shares at a consolidation ratio to be determined by the Managing Board, subject to the approval of the Supervisory Board (the reverse stock split);
(c)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment of the Company's Articles of Association (Part III) to decrease the par value per ordinary share to an amount of EUR 0.01 and to repay to the shareholders an amount to be determined by the Managing Board, subject to the approval of the Supervisory Board, which amount will at maximum be USD 300 million in the aggregate;
(d)Proposal to authorize each member of the Managing Board of the Company and each lawyer, (candidate) civil law notary and paralegal working at De Brauw Blackstone Westbroek N.V. to execute the three deeds of amendment of the Company's Articles of Association (Part I, II and III)
15.Cancellation of fractional ordinary shares held by the Company
16.Approval of the QIAGEN N.V. 2023 Stock Plan
17.Questions
18.Closing
|
| 2023-11-01 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Opening
2.Managing Board Report for the year ended December 31, 2022 ("Calendar Year 2022")
3.Supervisory Board Report on the Company's Annual Accounts (the "Annual Accounts") for Calendar Year 2022
4.Adoption of the Annual Accounts for Calendar Year 2022
5.Advisory Vote on the Remuneration Report 2022
6.Reservation and dividend policy
7.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2022
8.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2022
9.Reappointment of the following eight Supervisory Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2024
10.Reappointment of the following two Managing Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2024
11.Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2023
12.Authorization of the Supervisory Board, until December 22, 2024 to (voting items):
(a)issue a number of ordinary shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of the shares issued and outstanding in the capital of the Company as at December 31, 2022 as included in the Annual Accounts for Calendar Year 2022;
(b)restrict or exclude the pre-emptive rights with respect to issuing ordinary shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2022
13.Authorization of the Managing Board, until December 22, 2024, to acquire shares in the Company's own share capital
14.Discretionary rights for the Managing Board to implement a capital repayment by means of a synthetic share repurchase (voting item):
(a)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment to the Company's Articles of Association (Part I) to, amongst other things, increase the par value per ordinary share in the share capital of the Company by an amount to be determined by the Managing Board of the Company;
(b)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment of the Company's Articles of Association (Part II) to, amongst other things, consolidate the ordinary shares at a consolidation ratio to be determined by the Managing Board, subject to the approval of the Supervisory Board (the reverse stock split);
(c)Proposal to amend the Company's Articles of Association in accordance with the draft deed of amendment of the Company's Articles of Association (Part III) to decrease the par value per ordinary share to an amount of EUR 0.01 and to repay to the shareholders an amount to be determined by the Managing Board, subject to the approval of the Supervisory Board, which amount will at maximum be USD 300 million in the aggregate;
(d)Proposal to authorize each member of the Managing Board of the Company and each lawyer, (candidate) civil law notary and paralegal working at De Brauw Blackstone Westbroek N.V. to execute the three deeds of amendment of the Company's Articles of Association (Part I, II and III)
15.Cancellation of fractional ordinary shares held by the Company
16.Approval of the QIAGEN N.V. 2023 Stock Plan
17.Questions
18.Closing
|
| 2022-11-09 |
股东大会：
将于2022-06-23召开股东大会
会议内容 ▼▲
- 1.Opening
2.Managing Board Report for the year ended December 31, 2021 (“Calendar Year 2021”)
3.Supervisory Board Report on the Company’s Annual Accounts (the “Annual Accounts”) for Calendar Year 2021
4.Adoption of the Annual Accounts for Calendar Year 2021
5.Advisory Vote on the Remuneration Report 2021
6.Reservation and dividend policy
7.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2021
8.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2021
9.Appointment and reappointment of the following eight Supervisory Directors of the Company for a term running up to and including the day of the Annual General Meeting in 2023
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-02 |
股东大会：
将于2021-06-29召开股东大会
会议内容 ▼▲
- 1.Opening;
2.Managing Board Report for the year ended December 31, 2020 (“Calendar Year 2020”);
3.Supervisory Board Report on the Company’s Annual Accounts (the “Annual Accounts”) for Calendar Year 2020;
4.Adoption of the Annual Accounts for Calendar Year 2020 (voting item);
5.Advisory Vote on the Remuneration Report 2020 (advisory voting item);
6.Reservation and dividend policy;
7.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2020 (voting item);
8.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2020 (voting item);
9.Reappointment of the following seven Supervisory Directors of the Company for a term running up to and including the day of the Annual General Meeting in 2022 (voting items):
(a)Dr. Metin Colpan;
(b)Mr. Thomas Ebeling;
(c)Dr. Toralf Haag;
(d)Prof. Dr. Ross L. Levine;
(e)Prof. Dr. Elaine Mardis;
(f)Mr. Lawrence A. Rosen;
(g)Ms. Elizabeth E. Tallett
10.Reappointment of the following two Managing Directors of the Company for a term running up to and including the day of the Annual General Meeting in 2022 (voting items):
(a)Mr. Thierry Bernard;
(b)Mr. Roland Sackers.
11.Adoption of the Remuneration Policy with respect to the Managing Board (voting item);
12.Remuneration of the members of the Supervisory Board (voting items):
(a)Partial amendment of the Remuneration Policy with respect to the Supervisory Board;
(b)Determination of the remuneration of the members of the Supervisory Board.
13.Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2021 (voting item);
14.Authorization of the Supervisory Board, until December 29, 2022 to (voting items):
(a)issue a number of ordinary shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of shares issued and outstanding in the capital of the Company as at December 31, 2020 as included in the Annual Accounts for Calendar Year 2020;
(b)restrict or exclude the pre-emptive rights with respect to issuing ordinary shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2020;
(c)solely for the purpose of strategic transactions such as mergers, acquisitions or strategic alliances, restrict or exclude the pre-emptive rights with respect to issuing additional ordinary shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2020;
15.Authorization of the Managing Board, until December 29, 2022, to acquire shares in the Company’s own share capital (voting item);
16.Amendment of the Company's Articles of Association in connection with changes to Dutch law (voting item);
17.Questions;
18.Closing.
|
| 2019-08-01 |
股东大会：
将于2019-06-17召开股东大会
会议内容 ▼▲
- 1.Opening;
2.Managing Board Report for the year ended December 31, 2018 (“Calendar Year 2018”);
3.a. Supervisory Board Report on the Company’s Annual Accounts (the “Annual Accounts”) for Calendar Year 2018;
b. Report of the Compensation Committee of the Supervisory Board for Calendar Year 2018;
4.Adoption of the Annual Accounts for Calendar Year 2018 (voting item);
5.Reservation and dividend policy;
6.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2018 (voting item);
7.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2018 (voting item);
8.Reappointment of the following seven Supervisory Directors of the Company for a one year term ending at the close of the Annual General Meeting in 2020 (voting items):
a. Mr. Stephane Bancel;
b. Dr. Hakan Bjorklund;
c. Dr. Metin Colpan;
d. Prof. Dr. Ross L. Levine;
e. Prof. Dr. Elaine Mardis;
f. Mr. Lawrence A. Rosen;
g. Ms. Elizabeth E. Tallett
9.Reappointment of the following two Managing Directors of the Company for a term ending on the date of the Annual General Meeting in 2020 (voting items):
a. Mr. Peer M. Schatz;
b. Mr. Roland Sackers;
10.Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2019 (voting item);
11.Authorization of the Supervisory Board, until December 17, 2020 to:
a. issue a number of Common Shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of shares issued and outstanding in the capital of the Company as at December 31, 2018 as included in the Annual Accounts for Calendar Year 2018, (voting item);
b. restrict or exclude the pre-emptive rights with respect to issuing Common Shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2018 (voting item);
c. solely for the purpose of strategic transactions such as mergers, acquisitions or strategic alliances, to restrict or exclude the pre-emptive rights with respect to issuing additional Common Shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2018 (voting item);
12.Authorization of the Managing Board, until December 17, 2020, to acquire shares in the Company’s own share capital (voting item);
13.Resolution to amend the Company's Articles of Association (voting item);
14.Questions;
15.Closing
|
| 2017-07-31 |
股东大会：
将于2017-06-21召开股东大会
会议内容 ▼▲
- 1.Opening;
2.Managing Board Report for the year ended December 31, 2016 (“Calendar Year 2016”);
3.a. Supervisory Board Report on the Company’s Annual Accounts (the “Annual Accounts”) for Calendar Year 2016;
b. Report of the Compensation Committee of the Supervisory Board for Calendar Year 2016;
4.Adoption of the Annual Accounts for Calendar Year 2016 (voting item);
5.Reservation and dividend policy;
6.Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2016 (voting item);
7.Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2016 (voting item);
8.(Re-)Appointment of the following eight Supervisory Directors of the Company for a one year term ending at the close of the Annual General Meeting in 2018 (voting items):
a.Mr. Stephane Bancel;
b.Dr. Hakan Bjorklund;
c.Dr. Metin Colpan;
d.Prof. Dr. Manfred Karobath;
e.Prof. Dr. Ross L. Levine;
f.Prof. Dr. Elaine Mardis;
g.Mr. Lawrence A. Rosen;
h.Ms. Elizabeth E. Tallett
9.Reappointment of the following two Managing Directors of the Company for a term ending on the date of the Annual General Meeting in 2018 (voting items):
i.Mr. Peer M. Schatz;
j.Mr. Roland Sackers
10.Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2017 (voting item);
11.Authorization of the Supervisory Board, until December 21, 2018 to:
a.issue a number of Common Shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2016 as included in the Annual Accounts for Calendar Year 2016, (voting item);
b.restrict or exclude the pre-emptive rights with respect to issuing shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of twenty percent (20%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2016 (voting item);
12.Authorization of the Managing Board, until December 21, 2018, to acquire shares in the Company’s own share capital (voting item);
13.Questions;
14.Closing.
|